# EDGAR Filing Document

**Accession Number:** 0001826667
**File Stem:** 0001628280-26-016490
**Filing Date:** 2026-3
**Character Count:** 26952
**Document Hash:** d9b279790785e3ee7a913b65fa1fca56
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-016490.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001628280-26-016490

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**EFFECTIVENESS DATE**: 20260310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TriSalus Life Sciences, Inc.
- **CENTRAL INDEX KEY:** 0001826667
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 853009869
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294187
- **FILM NUMBER:** 26739869

**BUSINESS ADDRESS:**
- **STREET 1:** 6272 WEST 91ST AVENUE
- **CITY:** WESTMINSTER
- **STATE:** CO
- **ZIP:** 80031
- **BUSINESS PHONE:** 415 336 8917

**MAIL ADDRESS:**
- **STREET 1:** 6272 WEST 91ST AVENUE
- **CITY:** WESTMINSTER
- **STATE:** CO
- **ZIP:** 80031

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MedTech Acquisition Corp
- **DATE OF NAME CHANGE:** 20200930

**As filed with the Securities and Exchange Commission on March 10, 2026** 

Registration No. 333-

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT** 

**UNDER THE SECURITIES ACT OF 1933**

**TRISALUS LIFE SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **85-3009869** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S Employer Identification No.) |

---

---

| | |
|:---|:---|
| **6272 W. 91st Ave.**<br>**Westminster, Colorado**  | **80031** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan**

**TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan**

(Full Title of the Plan)

**Mary Szela**

**Chief Executive Officer**

**6272 W. 91st Ave.**

**Westminster, Colorado 80031**

(Name and address of agent for service)

**Tel: (303) 426 -1222**

(Telephone number, including area code, of agent for service)

**Copy to:**

**Jeffrey Fessler, Esq.**

**Sheppard, Mullin, Richter & Hampton LLP**

**30 Rockefeller Plaza**

**New York, NY 10112-0015**

**(212) 653-8700**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act:

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
| | | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

------

**REGISTRATION OF ADDITIONAL SHARES**

**PURSUANT TO GENERAL INSTRUCTION E** 

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the registrant on Form S-8 relating to the same employee benefit plans is effective.

The registrant previously registered shares of its Common Stock for issuance under the registrant's 2023 Equity Incentive Plan (the "2023 EIP") and 2023 Employee Stock Purchase Plan (the "2023 ESPP") under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the "Commission") on <u>[October 16, 2023](https://www.sec.gov/Archives/edgar/data/1826667/000110465923109417/tm2328410d1_s8.htm)</u> (File No. 333-275009), <u>[April 11, 2024](https://www.sec.gov/Archives/edgar/data/1826667/000110465924046365/tm2411596d1_s8.htm)</u> (File No. 333-278627) and <u>[April 25, 2025](https://www.sec.gov/Archives/edgar/data/1826667/000110465925039521/tm2513131d3_s8.htm)</u> (File No. 333-286781) (collectively, the ***"Prior Registration Statements"***). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statement referenced above.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents filed by the registrant with the Commission are hereby incorporated by reference in this registration statement (in each case excluding any information furnished and not filed according to applicable rules, such as information furnished pursuant to Item 2.02 or Item 7.01 on any Current Report on Form 8-K):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the registrant's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Commission on <u>[March](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/tlsi-20251231.htm)[5, 2026](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/tlsi-20251231.htm)</u>;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the registrant's Current Reports on Form 8-K filed with the Commission on <u>[February 9,](https://www.sec.gov/Archives/edgar/data/1826667/000162828026006219/tlsi-20260203.htm)[2026](https://www.sec.gov/Archives/edgar/data/1826667/000162828026006219/tlsi-20260203.htm)</u>, and <u>[February 20, 2026](https://www.sec.gov/Archives/edgar/data/1826667/000149315226007598/form8-k.htm)</u>; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the description of the Registrant's securities contained in the Registration Statement on Form 8-A filed with the Commission on <u>[December 16, 2020](https://www.sec.gov/Archives/edgar/data/1826667/000110465920136193/tm2034341d8_8a12b.htm)</u>, as updated by <u>[Exhibit 4.5](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/ex45descriptionofsecurities.htm)</u> to the registrant's Annual Report on Form 10-K filed with the Commission on March 5, 2026, as well as any additional amendments or reports filed with the Commission for the purpose of updating the description.

All reports and other documents filed by the registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than current reports furnished under Item 2.02 and Item 7.01 of Form 8-K and any exhibits furnished on such form that relate to such items, after the date of this Registration Statement, and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

------

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| <u>[4.1](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex3-1.htm)</u> | <u>[Second Amended and Restated Certificate of Incorporation of TriSalus Life Sciences, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on August 16, 2023).](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex3-1.htm)</u> |
| <u>[4.2](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex3-2.htm)</u> | <u>[Amended and Restated Bylaws of TriSalus Life Sciences, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on August 16, 2023).](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex3-2.htm)</u> |
| <u>[4.3](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex4-1.htm)</u> | <u>[Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on August 16, 2023).](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex4-1.htm)</u> |
| <u>[5.1\*](ex51opinionofsheppardmullin.htm)</u> | <u>[Opinion of](ex51opinionofsheppardmullin.htm)[Sheppard, Mullin, Richter & Hampton](ex51opinionofsheppardmullin.htm)[LLP](ex51opinionofsheppardmullin.htm)</u> |
| <u>[23.1\*](ex231grantthorntonconsent.htm)</u> | <u>[Consent of Grant Thornton LLP, independent registered public accounting firm.](ex231grantthorntonconsent.htm)</u> |
| <u>[23.2\*](ex51opinionofsheppardmullin.htm)</u> | <u>[Consent of](ex51opinionofsheppardmullin.htm)[Sheppard, Mullin, Richter & Hampton LLP](ex51opinionofsheppardmullin.htm)[(included in Exhibit 5.1).](ex51opinionofsheppardmullin.htm)</u> |
| <u>[24.1\*](#i0102f5a8a9a94f43bede745ef73c5a7f_125)</u> | <u>[Power of Attorney (contained on the signature page hereto).](#i0102f5a8a9a94f43bede745ef73c5a7f_125)</u> |
| <u>[99.1](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-21.htm)</u> | <u>[TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.21 to the Current Report on Form 8-K filed on August 16, 2023).](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-21.htm)</u> |
| <u>[99.2](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-24.htm)</u> | <u>[TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.24 to the Current Report on Form 8-K filed on August 16, 2023).](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-24.htm)</u> |
| <u>[9](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-22.htm)[9.3](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-22.htm)</u> | <u>[Form of Stock Option Grant Notice and Form of Stock Option Agreement under 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.22 to the Current Report on Form 8-K filed on August 16, 2023).](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-22.htm)</u> |
| <u>[99.4](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-23.htm)</u> | <u>[Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Agreement under 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.23 to the Current Report on Form 8-K filed on August 16, 2023).](https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-23.htm)</u> |
| <u>[107\*](exfilingfees.htm)</u> | <u>[Filing Fee Table.](exfilingfees.htm)</u> |

---

\* Filed herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Westminster, State of Colorado, on March 10, 2026.

---

| | | |
|:---|:---|:---|
| **TRISALUS LIFE SCIENCES, INC.** | **TRISALUS LIFE SCIENCES, INC.** | **TRISALUS LIFE SCIENCES, INC.** |
| By: | /s/ Mary Szela | /s/ Mary Szela |
|  | Name: | Mary Szela |
|  | Title: | Chief Executive Officer |

---

------

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mary Szela and David Patience, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Mary Szela | Chief Executive Officer, President and Director | March 10, 2026 |
| Mary Szela | (*Principal Executive Officer*) |  |
| /s/ David Patience | Chief Financial Officer | March 10, 2026 |
| David Patience | (*Principal Financial and Accounting Officer*) |  |
| /s/ Mats Wahlström | Chairman of the Board of Directors | March 10, 2026 |
| Mats Wahlström |  |  |
| /s/ Michael P. Stansky | Director | March 10, 2026 |
| Michael P. Stansky |  |  |
| /s/ Gary Gordon | Director | March 10, 2026 |
| Gary Gordon |  |  |
| /s/ Kerry Hicks | Director | March 10, 2026 |
| Kerry Hicks |  |  |
| /s/ David J. Matlin | Director | March 10, 2026 |
| David J. Matlin |  |  |
| /s/ William Valle | Director | March 10, 2026 |
| William Valle |  |  |

---

## Exhibit 5.1

**EXHIBIT 5.1**

![image_0.jpg](image_0.jpg)

March 10, 2026

**<u>VIA ELECTRONIC MAIL ONLY</u>**

TriSalus Life Sciences, Inc.

6272 W. 91<sup>st</sup> Ave.

Westminster, Colorado 80031

Re: <u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

You have requested our opinion with respect to certain matters in connection with the filing by TriSalus Life Sciences, Inc., a Delaware corporation (the "Company"), of a Registration Statement on Form S-8 (the "Registration Statement") under the Securities Act of 1933, as amended, with the Securities and Exchange Commission, covering the offering of up to 4,664,356 shares (the "Shares") of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), consisting of (a) 3,331,683 shares of Common Stock issuable pursuant to the Company's 2023 Equity Incentive Plan (the "2023 EIP") and (b) 1,332,673 shares of Common Stock issuable pursuant to the Company's 2023 Employee Stock Purchase Plan (together with 2023 EIP, the "Plans").

This Opinion is being furnished in accordance with the requirements of Item 8 of Form S-8 and Item 601(b)(5)(i) of Regulation S-K.

In connection with this opinion, we have reviewed and relied upon the Registration Statement, the Company's Certificate of Incorporation as in effect on the date hereof, the Company's Bylaws effective as in effect on the date hereof (the "Bylaws"), the proceedings taken by the Company with respect to the authorization and adoption of the Plans, resolutions adopted by the board of directors of the Company, and such other documents, records, certificates, memoranda and other instruments as we deem necessary as a basis for this opinion. With respect to the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity to original of all documents submitted to us as certified or reproduced copies. We have also assumed that the Shares will be uncertificated in accordance with Section 158 of the Delaware General Corporation Law, and the transfer agent therefor will register the purchaser thereof as the registered owner of any uncertificated Shares on its stock transfer books and records. We have further assumed that (a) shares of the Common Stock currently reserved for issuance under the Plans will remain available for the issuance of the Shares, and (b) neither the Company's charter documents nor any of the proceedings relating to either the Plans or any of the award agreements relating to the Shares will be rescinded, amended or otherwise modified prior to the issuance of the Shares. We have also obtained from public officials and officers of the Company certificates or comparable documents as to certain factual matters and, insofar as this opinion is based on matters of fact, we have relied on such certificates and comparable documents without independent investigation. We have made such other investigations as we have deemed relevant and necessary in connection with the opinions hereinafter set forth.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when issued and sold in the manner referred to in the Plans against proper payment and consideration thereof and pursuant to the agreements that accompany the Plans, will be legally and validly issued, fully paid and nonassessable.

------

We consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.

We express no opinion as to matters governed by any laws other than the Delaware General Corporation Law and reported decisions of the Delaware courts interpreting such law.

This opinion letter is rendered as of the date first written above, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. Our opinion is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company, the Shares, the Plans, the award agreements related to the Shares or the Registration Statement.

Respectfully Submitted,

/s/ Sheppard, Mullin, Richter & Hampton LLP

SHEPPARD, MULLIN, RICHTER & HAMPTON LLP

## Exhibit 23.1

**EXHIBIT 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We have issued our report dated March 5, 2026 with respect to the consolidated financial statements of TriSalus Life Sciences, Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2025, which is incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in this Registration Statement.

/s/ GRANT THORNTON LLP

Chicago, Illinois<br>March 10, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **TriSalus Life Sciences, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan Common Stock, $0.0001 par value | Other | 3331683 | $4.543 | $15135835.87 | 0.0001381 | $2090.26 |
| 2 | Equity | TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan Common Stock, $0.0001 par value per share | Other | 1332673 | $3.862 | $5146783.13 | 0.0001381 | $710.77 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $20282619.00  |  | $2801.03  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $2801.03  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> 1a. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock, $0.0001 par value per share ("Common Stock"), of the Registrant which become issuable under the TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan (the "2023 EIP") and the TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan (the "2023 ESPP") by the reason of any stock dividend, stock split, recapitalization or any other similar transaction which results in an increase in the number of shares of the Registrant's outstanding Common Stock. 1b. Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(c) and (h) of the Securities Act based on the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Market on March 6, 2026, which date is within five business days prior to the filing of this Registration Statement. 1c. Represents additional shares of Common Stock reserved for future grant under the 2023 EIP as a result of an automatic increase in shares reserved thereunder on January 1, 2024, pursuant to the terms of the 2023 EIP. The 2023 EIP provides that an additional number of shares will automatically be added annually to the shares authorized under the 2023 EIP on January 1st of each year ending on (and including) January 1, 2033, in an amount equal to 5% of the total number of shares of Common Stock outstanding on a fully diluted basis on December 31 of the preceding year. Notwithstanding the foregoing, the board of directors of the Registrant (the "Board") may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> See Note 1a. 2a. Represents additional shares of Common Stock reserved for future grant under the 2023 ESPP as a result of an automatic increase in shares reserved thereunder on January 1, 2024, pursuant to the terms of the 2023 ESPP. The number of shares reserved for issuance under the 2023 ESPP will automatically increase on January 1st of each year ending on (and including) January 1, 2033, in an amount equal to the lesser of (i) 2% of the total number of shares of Common Stock outstanding on a fully diluted basis on December 31st of the preceding year, and (ii) 2,792,503 shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence. 2b. Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(c) and (h) of the Securities Act based on the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Market on March 6, 2026, which date is within five business days prior to the filing of this Registration Statement, multiplied by 85%. Pursuant to the 2023 ESPP, the purchase price of the shares of Common Stock will be 85% of the lesser of the fair market value of the Common Stock on the Offering Date or the Purchase Date (each as defined int he 2023 ESPP).

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---